A validated mathematical model of FGFR3-mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer

Bladder cancer is a common malignancy with over 80,000 estimated new cases and nearly 18,000 deaths per year in the United States alone. Therapeutic options for metastatic bladder cancer had not evolved much for nearly four decades, until recently, when five immune checkpoint inhibitors were approve...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuneye, Kamaldeen, Bergman, Daniel, Bloodworth, Jeffrey C., Pearson, Alexander T., Sweis, Randy F., Jackson, Trachette L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722426/
https://www.ncbi.nlm.nih.gov/pubmed/34984415
http://dx.doi.org/10.1002/cso2.1019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722426/
https://www.ncbi.nlm.nih.gov/pubmed/34984415
http://dx.doi.org/10.1002/cso2.1019

Ejemplares similares